Symbiotec Pharmalab IPO: ₹1,757 Crore API Maker's Issue That Listed Flat
Symbiotec Pharmalab IPO opened on August 24, 2026, with a price band of ₹938 to ₹988. Check the subscription status, IPO timeline, financials and peer comparison.
Symbiotec Pharmalab IPO: The ₹1,757 crore issue, a ₹150 crore fresh issue plus a ₹1,607 crore offer for sale, was open from 24 to 27 August 2026 at ₹938 to ₹988 per share. Allotment took place on 28 August, and the shares listed on the NSE at ₹988 on 1 September 2026, exactly the issue price.
Symbiotec Pharmalab IPO: Symbiotec Pharmalab is a pharmaceutical and biotechnology company that manufactures APIs, nutritional ingredients and specialty products for domestic and international markets.
The company came to market with a ₹1,757.00 Cr IPO, which was a combination of fresh issue and OFS. Here are the key details of the Symbiotec Pharmalab IPO.
Symbiotec Pharmalab IPO Details
Here are the key dates and issue details.
-
Symbiotec Pharmalab IPO is worth ₹1,757.00 cr, and the issue is a combination of a fresh issue of ₹150 cr and offer for sale of ₹1,607 cr.
-
Symbiotec Pharmalab IPO opened for subscription on 24 Aug 2026 and closed on 27 Aug 2026. The price band was set between ₹938 to ₹988
-
Symbiotec Pharmalab IPO’s allotment took place on 28 Aug 2026 and the shares were listed on the BSE and NSE on 1 Sep 2026.
-
The promoter and Promoter Group held 34.47% before the IPO, which came down after listing.
-
The company planned to use ₹112.50 crore for debt repayment, and the balance for general corporate purposes.
-
MUFG Intime India Pvt.Ltd was the registrar for the Symbiotec Pharmalab IPO.
|
Parameter |
Detail |
|---|---|
|
IPO Open Date |
24 Aug 2026 |
|
IPO Close Date |
27 Aug 2026 |
|
Allotment Date |
28 Aug 2026 |
|
Listing Date |
1 Sep 2026 (BSE & NSE) |
|
Price Band |
₹938 to ₹988 per share |
|
Lot Size |
15 shares |
|
Minimum Investment |
₹14,820 |
|
Fresh Issue |
₹150 Cr |
|
Offer for Sale (OFS) |
₹1607 Cr |
|
Total Issue Size |
₹1,757 Cr |
Symbiotec Pharmalab IPO Listing Performance
The grey market premium ahead of listing had suggested a gain of about 29%. The flat debut was a clear miss against that signal, and a reminder that a mostly offer-for-sale issue at a full valuation leaves little on the table.
About Symbiotec Pharmalab IPO
Incorporated in 2002, Symbiotec Pharmalab is a pharmaceutical and biotechnology company that makes APIs, nutritional ingredients and specialty products for Indian and overseas markets.
With over 30 years of industry experience, the company has grown from a small-scale steroidal hormone API manufacturer in 1995 into an integrated manufacturing business. It holds approvals from US FDA, EU-GMP, South Korea’s Ministry of Food and Drug Safety and other global regulators.
The company focuses on research, quality standards and sustainable manufacturing. Its products serve the pharmaceutical, nutraceutical and wellness industries.
READ THIS: Augmont Enterprises IPO Review
Strengths (from DRHP)
- Dominant global position in niche API segments — 38.2% global volume share in corticosteroid APIs, 23.8% in steroidal-hormone APIs (as of March 2026)
- Over 80% backward integration through in-house precursor production, across three interconnected manufacturing platforms
- Clean regulatory compliance record — 108 customer and regulatory inspections passed
- Consistent CARE A+ credit rating; 200+ customers across 40+ countries (international markets = 67% of FY2026 revenue)
Risk Factors (from DRHP)
- High product concentration — APIs are 96.07% of revenue; top 5 products alone are 62.27%
- Two facilities (Ujjain, Mhow) commissioned in FY2026 remain at pilot scale with pending regulatory approvals
- ROE declined to 11.19% in FY2026 from 14.98% in FY2024
- Heavy dependence on foreign markets brings currency and regulatory risk; CDMO/complex-injectables is still only 3.93% of revenue with limited operating history
Symbiotec Pharmalab IPO Reservation
For Symbiotec Pharmalab IPO, 35% of the issue has been reserved for retail investors. The table below shows the allocation across different investor categories.
|
Investor Category |
Shares Offered |
|---|---|
|
QIB Investors |
50% |
|
Retail Investors |
35% |
|
NII (HNI) Investors |
15% |
Symbiotec Pharmalab IPO Lot Size
Retail investors could apply for a minimum of 1 lot, which includes 15 shares costing ₹14,820. Maximum investment allowed for retail investors is 13 lots, which totals 195 shares and costs ₹1,92,660
|
Application |
Lots |
Shares |
Amount (₹) |
|---|---|---|---|
|
Retail (Min) |
1 |
15 |
14,820 |
|
Retail (Max) |
13 |
195 |
1,92,660 |
|
S-HNI (Min) |
14 |
210 |
2,07,480 |
|
S-HNI (Max) |
67 |
1,005 |
9,92,940 |
|
B-HNI (Min) |
68 |
1,020 |
10,07,760 |
Symbiotec Pharmalab IPO Financial Performance
Symbiotec Pharmalab reported a PAT of ₹ 109.90 Cr as of 31 March 2026, up from ₹100.06 Cr in FY24. Over the past 3 years, the company’s PAT and PAT margin have grown steadily. All financial details are provided in the table below.
|
Period Ended |
31 Mar 2026 |
31 Mar 2025 |
31 Mar 2024 |
|---|---|---|---|
|
Revenue from Ops (₹ Cr) |
869.15 |
751.55 |
716.25 |
|
Total Income (₹ Cr) |
872.26 |
755.98 |
723.33 |
|
EBITDA (₹ Cr) |
231.97 |
206.11 |
177.04 |
|
EBITDA Margin (%) |
26.59 |
27.26 |
24.48 |
|
PAT (₹ Cr) |
109.90 |
96.79 |
100.06 |
|
PAT Margin (%) |
12.60 |
12.80 |
13.83 |
|
ROE (%) |
11.19 |
12.66 |
14.98 |
|
ROCE (%) |
11.56 |
11.80 |
14.03 |
Source: Symbiotec Pharmalab IPO RHP
Symbiotec Pharmalab IPO Peer Comparison from RHP
Symbiotec Pharmalab IPO has a decent EPS among its peers. Higher EPS is always considered better. Below is a brief comparison of Symbiotec Pharmalab IPO.
|
Company |
EPS Diluted |
P/E (X) |
|---|---|---|
|
Laurus Labs |
16.45 |
109.36 |
|
Cohance Lifesciences |
4.68 |
95.02 |
|
Divi's Laboratories |
96.75 |
87.8 |
|
Concord Biotech |
24.78 |
61.07 |
|
Symbiotec Pharmalab |
19 |
— |
Source: RHP
Conclusion
Symbiotec Pharmalab IPO was a ₹1,757 crore issue, of which only ₹150 crore was a fresh issue and ₹1,607 crore an offer for sale, priced at ₹938 to ₹988 per share. The company manufactures APIs, nutritional ingredients and specialty products and reported healthy profit margins. It planned to use ₹112.50 crore for debt repayment. The shares listed flat at ₹988 on 1 September 2026. With the promoter stake already at 34.47% before the issue, investors should watch capacity utilisation and regulatory approvals rather than expect a listing pop that never came.
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.